ClearPoint Neuro (CLPT) Stock Price, News & Analysis

Company Overview

ClearPoint Neuro, Inc. develops and commercializes image-guided systems designed to support minimally invasive procedures involving the brain. Its technology is intended to help physicians plan, navigate and monitor neurosurgical interventions while using magnetic resonance imaging (MRI) guidance.

The company’s principal product is the ClearPoint Neuro Navigation System, which combines specialized software, MRI-compatible instruments and accessories to assist with procedures such as deep brain stimulation, laser ablation and the delivery of therapeutic agents to targeted areas of the brain. ClearPoint Neuro also provides related products and services for clinical research, pharmaceutical development and advanced biologic delivery.

The company was previously known as MRI Interventions, Inc. and adopted the ClearPoint Neuro name in 2020. Based in Solana Beach, California, ClearPoint Neuro serves hospitals, physicians, research institutions and life-sciences partners in the United States and selected international markets. Joe Burnett serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $11.54 to $12.50
• 50-Day Range: $11.77 to $16.96
• 52-Week Range: $8.27 to $30.10
• Volume: 320,785 shs
• Average Volume: 714,640 shs
• Market Capitalization: $381.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.67
• Consensus Rating: Hold

ClearPoint Neuro Stock Analysis - MarketRank™

ClearPoint Neuro scored higher than 41% of companies evaluated by MarketBeat, and ranked 593rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

ClearPoint Neuro has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ClearPoint Neuro has a consensus price target of $25.67, representing about 105.3% upside from its current price of $12.50.

Amount of Analyst Coverage

ClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($1.22) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ClearPoint Neuro is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ClearPoint Neuro is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ClearPoint Neuro has a P/B Ratio of 12.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.25% of the float of ClearPoint Neuro has been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 6.92.

Change versus previous month

Short interest in ClearPoint Neuro has recently increased by 3.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ClearPoint Neuro does not currently pay a dividend.

Dividend Growth

ClearPoint Neuro does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.21

News Sentiment

ClearPoint Neuro has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ClearPoint Neuro this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.94% of the stock of ClearPoint Neuro is held by insiders.

Percentage Held by Institutions

30.08% of the stock of ClearPoint Neuro is held by institutions.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CLPT
• CIK: 1285550
• Web: www.clearpointneuro.com
• Phone: (949) 900-6833
• Fax: 949-900-6834
• Employees: 172
• Year Founded: 1998

Price Target and Rating

• Average Price Target for ClearPoint Neuro: $25.67
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: +105.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.54 million
• Net Margins: -81.76%
• Pretax Margin: -81.80%
• Return on Equity: -188.09%
• Return on Assets: -40.88%

Debt

• Debt-to-Equity Ratio: 4.66
• Current Ratio: 4.74
• Quick Ratio: 3.89

Sales & Book Value

• Annual Sales: $42.28 million
• Price / Sales: 9.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.99 per share
• Price / Book: 12.63

Miscellaneous

• Outstanding Shares: 30,504,000
• Free Float: 28,387,000
• Market Cap: $381.42 million
• Optionable: Optionable
• Beta: 1.26